To address the effect of the knockdown of Ddit3 in tumor-induced CD8+ T cell tolerance, we used an adoptive cellular therapy model against the melanoma tumor antigen gp100, in which pre-activated anti-gp10025–33 transgenic CD90.1+ Pmel T cells were transferred into CD90.2+ congenic mice bearing established B16 melanoma tumors (Fig. 6a). This evidence concerns the gene PMEL and melanoma.